Cardiology

Sephy Philip, PharmD, discussed the results of the ANCHOR trial, as well as the subgroup analysis.

Steve Deitelzweig, MD, discussed the real-world usage of direct-acting anticoagulants in comparison with the conventional warfarin, as well as the benefits they have shown based on a large data analysis.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

Researchers note that efforts are needed to align clinical practice with clinical guidelines.

The devices have received expanded indication for use in femoral vein closures in addition to previous approval for arterial closures.

Since March 10, almost 100 patients have presented to EDs with vitamin K-dependent coagulopathy, which has been linked to synthetic cannabinoid use.

Physical and social improvements were observed in the 8-month visit, but importantly, were sustained in the 3-year follow-up period.

The decision was made with data from the REDUCE study, which showed a 77% reduction in recurrent ischemic stroke in the patients who underwent PFO closure with the device.

Find out what you know and what you may need to brush up on in the primary and secondary prevention of CVD.

Results of a new study of causes of elevated LDL in young women supports greater focus on early assessment and intervention in this population.

The first patient has been dosed in MyoKardia’s Phase 2 MAVERICK-HCM clinical trial of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy patients.

The Pfizer molecule previously received a Fast Track designation by the FDA in June 2017.

Justin Davies, MBBS, MRCP, PhD, discussed the cost-effectiveness analysis of the DEFINE-FLAIR trial comparing iFR and FFR for patients requiring PCI.

When a physician becomes famous, opportunities abound. How can they ensure they’re leveraging the limelight responsibly?

The association between long-term antibiotic use and death is especially noticeable while looking at death from heart disease.

In the ATTR-ACT study, tafamidis exhibited a statistically significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations in transthyretin cardiomyopathy patients.

The success of VNS during post-stroke rehab has led to the enrolling of a clinical trial to test the therapy in patients who have experienced a stroke.

Data presented at the 16th International Symposium on Amyloidosis in Japan were presented this morning, showing that inotersen-treated patients with hATTR amyloidosis continued to exhibit sustained benefit.

Participants taking anti-depressants 36% more likely to develop atrial fibrillation.

The survey estimates from the National Center for Health Statistics report that more people are vaccinating for flu and testing for HIV.

Positive data from a Phase 3 study of inotersen (IONIS-TTRx) in patients with hereditary ATTR amyloidosis was presented at the 2018 American College of Cardiology Annual Meeting.

With the ongoing rollout of Mayo Clinic’s new EHR system, Epic, the hospital continues to build on its commitment to integrated care that patients have come to expect.

Kevin Maki discussed the constant need for more options, the importance of balancing the cost and benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and the impact of the new hypertension guidelines.

In recent years, cholesteryl ester transfer protein (CETP) inhibition has become contentious in lipidology and cardiology circles. Many believe that we have reached the end of the CETP inhibition class, and not without good reason—many drug makers have failed to bring the class to market.

Although the factor Xa (FXa) inhibitor oral anticoagulants have fewer drug interactions and are without burdens associated with warfarin, such as blood test monitoring, dosage adjustment, and diet restriction, they also lack an approved antidote to their anticoagulant effect.